Walpar Nutritions Limited (NSE:WALPAR)

India · Delayed Price · Currency is INR

25.00

-1.10 (-4.21%)

At close: Oct 28, 2026

Market Cap	234.76M -43.2%
Revenue (ttm)	836.13M +10.4%
Net Income	24.25M +4.0%
EPS	2.59 +4.0%
Shares Out	9.39M
PE Ratio	9.67
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,000
Open	25.00
Previous Close	26.10
Day's Range	25.00 - 25.00
52-Week Range	21.25 - 50.60
Beta	-0.60
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 5, 2026

About Walpar Nutritions

Walpar Nutritions Limited manufactures and trades pharmaceutical, nutraceutical, herbal, and ayurvedic commodities in India. The company offers G-Flora, a probiotic blend for gut health and immunity; Inosia-F, an inositol supplement for female hormal balance; Inovam Plus, a multivitamin; Ironica-CR, a controlled-release iron supplement; Myobest, a muscle support formula; Ovality for ovarian health support; Ovanyx-F, a female reproductive health supplement; Ovacon-F for women's fertility support; PCOS Care Forte for PCOS support; Procive-F, fema... [Read more]

Industry Pharmaceutical Preparations

Founded 2009

Country India

Stock Exchange National Stock Exchange of India

Ticker Symbol WALPAR

Full Company Profile

Financial Performance

In fiscal year 2026, Walpar Nutritions's revenue was 789.14 million, an increase of 9.66% compared to the previous year's 719.60 million. Earnings were 24.74 million, an increase of 6.45%.

Financial Statements